Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorRuijin Hospital
About this trial
DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.
Eligibility criteria
Qualifiers
Histology confirmed non-obstructive adenocarcinoma of stomach or esophago-gastric junction.
Clinical stage: Clinical Tumor-Node-Metastasis (cTNM:) stage III
Performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2 (normal to symptomatic but in bed less than half the day)
Clinically fit for systemic chemotherapy and gastric cancer surgery, i.e. adequate renal, hepatic, hematologic and pulmonary function.
Disqualifiers
Clinically unfit for systemic chemotherapy and gastric cancer surgery, i.e. uncontrolled cardiac disease, or other clinically significant uncontrolled comorbidities, unable to undergo general anesthesia
Distant metastases (including retroperitoneal lymph node)
Locally advanced inoperable disease (Clinical assessment)
Relapse of gastric cancer
Trial design
Treatments tested in this trial
- Chemotherapy
Treatment groups
246 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov